scholarly journals Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis

2015 ◽  
Vol 14 (4) ◽  
pp. 16372-16378 ◽  
Author(s):  
B.-S. Li ◽  
H. Liu ◽  
W.-L. Yang
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Poor Prognosis

Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients

2013 ◽  
Vol 134 (6) ◽  
pp. 1369-1378 ◽  
Author(s):  
Shiwei Guo ◽  
Wei Jing ◽  
Xiangui Hu ◽  
Xuyu Zhou ◽  
Lianjie Liu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Poor Prognosis

scholarly journals Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients

2007 ◽  
Vol 18 (10) ◽  
pp. 1660-1665 ◽  
Author(s):  
M. Mandalà ◽  
M. Reni ◽  
S. Cascinu ◽  
S. Barni ◽  
I. Floriani ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Poor Prognosis

Remnant pancreatic volume as an indicator of poor prognosis in pancreatic cancer patients after resection

Pancreatology ◽  
2019 ◽  
Vol 19 (5) ◽  
pp. 716-721 ◽  
Author(s):  
Ryoichi Miyamoto ◽  
Yukio Oshiro ◽  
Naoki Sano ◽  
Satoshi Inagawa ◽  
Nobuhiro Ohkohchi
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Pancreatic Volume

Elevation of Neutrophil-lymphocyte ratio at diagnosis is a biomarker of nutritional impairment and poor prognosis in pancreatic cancer patients

Pancreatology ◽  
2015 ◽  
Vol 15 (3) ◽  
pp. S86
Author(s):  
Matteo Piciucchi ◽  
Serena Stigliano ◽  
Giulia Zerboni ◽  
Livia Archibugi ◽  
Viola Barucca ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio

Prognostic Value of Long Non-Coding RNA Long Intergenic Non-Protein Coding RNA 1586 in Pancreatic Cancer

2021 ◽  
Vol 11 (3) ◽  
pp. 380-385
Author(s):  
Pengju Yue ◽  
Jing Bao
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Prognostic Value ◽  
Cancer Tissue ◽  
Non Coding Rna ◽  
Long Non Coding Rna ◽  
Low Expression ◽  
Related Survival

This study investigated the prognostic value of the long non-coding RNA (lncRNA) LINC01586 in pancreatic cancer. Three pancreatic cancer patients who received pancreaticoduodenectomies in our department in January 2019 were retrospectively selected. Cancer tissue and adjacent tissue samples were collected for high-throughput sequencing of lncRNAs. Among them, 221 lncRNAs were up-regulated and 235 were down-regulated. The expression of LINC01586 was decreased in pancreatic cancer patients (logFC = -3.308). An additional 74 tissue specimens were collected from pancreatic cancer patients from January 2011 to December 2016 for low-throughput validation. Patient samples were categorized into overexpression and low expression groups, based on the median LINC01586 expression level. The LINC01586 low expression group exhibited larger tumor size than the overexpression group (P < 0.001), while the low expression group exhibited a lower cancer-related survival rate than the overexpression group (one-year cancer-related survival rate: 55.6% vs. 89.2%, P < 0.001). Further analysis confirmed that low expression of LINC01586 was associated with poor prognosis for pancreatic cancer patients (OR = 0.169, 95% CI 0.066-0.437, P = 0.000). KEGG signaling pathway analysis was used to enrich LINC01586 target genes, and were mainly related to two metabolic pathways: insulin secretion (P = 0.011) and dopaminergic synapses (P = 0.0129), with SNAP25 as the core gene. The expression of LINC01586 and SNAP25were positively correlated in pancreatic cancer (R = 0.81 and P < 0.001). Together, our results indicate that LINC01586 may be used as a biomarker for prognosis predictions in pancreatic cancer patients, and its low expression is associated with poor prognosis.

scholarly journals Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients

Cell Cycle ◽  
2018 ◽  
Vol 17 (17) ◽  
pp. 2164-2174 ◽  
Author(s):  
Hui Wang ◽  
Ming Zhan ◽  
Ruimeng Yang ◽  
Yongheng Shi ◽  
Qiang Liu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
The Poor ◽  
Elevated Expression

Impact of pancreatic cancer treatment on hospice utilization.

2015 ◽  
Vol 33 (29_suppl) ◽  
pp. 52-52
Author(s):  
Lauren M Wancata ◽  
Huiying Yin ◽  
Sandra L. Wong
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Primary Treatment ◽  
Medicare Data ◽  
Hospice Use ◽  
Short Time ◽  
Incident Cases ◽  
The Impact

52 Background: There is an increasing incidence of pancreatic cancer over time, a cancer with a 5-year survival rate of only 7.2%.For patients with poor prognosis cancers, hospice is an important resource, but it is often not utilized or underutilized. Factors influencing hospice use are difficult to determine. We sought to evaluate the impact of pancreatic cancer treatment on hospice utilization. Methods: National Surveillance Epidemiology and End Results (SEER)-Medicare data was utilized to identify all incident cases of pancreatic cancer patients who died (2005-09, with follow up to 2011). Patients were stratified by primary treatment strategy: surgery, chemotherapy, or no treatment. Hospice utilization in the last 6 months of life, including average and median days enrolled in hospice and average time from diagnosis to hospice was evaluated. Results: 17,031 patients were identified, with 68.5% enrolling in hospice in the last 6 months of life. Patients undergoing surgery were less likely to enroll in hospice compared to patients not undergoing surgery (58.7% vs 69.4%, p < 0.0001). Interestingly, surgical patients spent on average 31.2 days in hospice (median 15.0 days) which was comparable to the non-surgical cohort (average 32.7 days, median 16.0 days; p = 0.32). Patients who received any chemotherapy spent an average of 29.2 days in hospice (median 15 days) compared to those who did not undergo chemotherapy, who spent an average of 34.5 days in hospice (median 16 days); p < 0.0001. While total hospice enrollment was equivalent between the chemotherapy and no chemotherapy cohorts (67.5% vs 69.1%), the time spent in hospice was significantly different (p < 0.0001). Patients not receiving any cancer-directed treatment enrolled in hospice at an average of 78.6 days (median 32 days) from diagnosis. Conclusions: Pancreatic cancer patients undergoing surgery enrolled in hospice to a much lesser extent than patients who did not have surgery. Patients not receiving cancer-directed treatment spend a relatively short time in hospice. Overall, hospice appears to be underutilized, and the majority of patients with this poor prognosis cancer are not realizing the full benefits of hospice.

Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients

2019 ◽  
Vol 517 (1) ◽  
pp. 84-88
Author(s):  
Tadashi Kegasawa ◽  
Tomohide Tatsumi ◽  
Teppei Yoshioka ◽  
Takahiro Suda ◽  
Kenji Ikezawa ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Binding Protein

scholarly journals Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients

Oncotarget ◽  
2017 ◽  
Vol 8 (67) ◽  
pp. 111333-111345 ◽  
Author(s):  
Luguang Chen ◽  
Chao Ma ◽  
Yun Bian ◽  
Chengwei Shao ◽  
Tiegong Wang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Aberrant Expression ◽  
E Cadherin
Sign in / Sign up

Export Citation Format

Share Document